Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 1024  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
CORRESPONDENCE
Year : 2019  |  Volume : 64  |  Issue : 4  |  Page : 330-331
Authors' reply - Antifungal resistance in dermatology


1 Department of Dermatology, Goa Medical College, Goa, India
2 Department of Microbiology, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India
3 Department of Dermatology, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India

Date of Web Publication5-Jul-2019

Correspondence Address:
Varadraj Pai
Department of Dermatology, Goa Medical College, Goa
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijd.IJD_614_18

Rights and Permissions



How to cite this article:
Pai V, Ganavalli A, Naveen K N. Authors' reply - Antifungal resistance in dermatology. Indian J Dermatol 2019;64:330-1

How to cite this URL:
Pai V, Ganavalli A, Naveen K N. Authors' reply - Antifungal resistance in dermatology. Indian J Dermatol [serial online] 2019 [cited 2019 Sep 16];64:330-1. Available from: http://www.e-ijd.org/text.asp?2019/64/4/330/262184




Sir,

We sincerely appreciate the interest of the author in our review article “Antifungal resistance in dermatology.”[1]

  1. Medical jargon is often described as the second language of healthcare professionals.[2] The authors agree that varied terminologies can add to the existing confusion. They thereby prefer to adhere to the existing nomenclature pending consensus


  2. Clinical resistance is defined as the failure to eradicate a fungal infection despite the administration of an antifungal agent with in vitro activity against the organism. Clinical resistance depends on various host and drug-related factors.[1] A knowledge of distinction between clinical and microbiological resistance is required for various causative factors and their therapeutic outcome.

  3. Ciclopirox olamine is approved as a topical formulation for superficial mycoses. Studies have shown that itraconazole and terbinafine have a lower minimum inhibitory concentration (MIC) than ciclopirox against Trichophyton rubrum and Trichophyton mentagrophytes.[3] Susceptibility tests on Candida albicans revealed a lower MIC for itraconazole and ketoconazole when compared to ciclopirox [4]


  4. Antimicrobial drug resistance is an almost inevitable process that is universal in the microbial world.[1] Ciclopirox also induces change in expression of genes encoding multidrug resistance efflux pumps CDR1 and CDR2.[5] Considering the above facts and the present nature of dermatophytosis, excessive reliance on any single topical medication for therapeutic goals may be unwarranted.

  5. The author highlighted the fungicide usage in agriculture and azole-resistant filamentous fungi in Indian settings.
  6. The main focus of our article remained the mechanism of antifungal resistance in dermatology and broad therapeutic outlines. A comprehensive review of antifungal resistance was beyond the scope of the article.


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Pai V, Ganavalli A, Kikkeri NN. Antifungal resistance in dermatology. Indian J Dermatol 2018;63:361-8.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Health Literacy for Interprofessional Education (IPE) eToolkit. Available from: https://pacificu.libguides.com/HLeT/JargonFreeTerms. [Last accessed on 2018 Nov 15].  Back to cited text no. 2
    
3.
Singh J, Zaman M, Gupta AK. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol 2007;45:595-602.  Back to cited text no. 3
    
4.
Danby CS, Boikov D, Rautemaa-Richardson R, Sobel JD. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother 2012;56:1403-6.  Back to cited text no. 4
    
5.
Lee RE, Liu TT, Barker KS, Lee RE, Rogers PD. Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. J Antimicrob Chemother 2005;55:655-62.  Back to cited text no. 5
    




 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (243 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed173    
    Printed1    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal